U.S. patent application number 10/519096 was filed with the patent office on 2005-11-17 for use of isoflavones for preparing topical compositions for promoting slimming, and related cosmetic treatment method.
This patent application is currently assigned to Laboratoires Expanscience. Invention is credited to Msika, Philippe, Piccardi, Nathalie.
Application Number | 20050256061 10/519096 |
Document ID | / |
Family ID | 29724931 |
Filed Date | 2005-11-17 |
United States Patent
Application |
20050256061 |
Kind Code |
A1 |
Msika, Philippe ; et
al. |
November 17, 2005 |
Use of isoflavones for preparing topical compositions for promoting
slimming, and related cosmetic treatment method
Abstract
The invention concerns the use of isoflavones for ping topical
compositions for promoting slimming, and in particular for fighting
against localized excess weight; the related cosmetic treatment
method and a composition comprising additionally to isoflavones an
extract of Sophora Japonica flowers.
Inventors: |
Msika, Philippe;
(Versailles, FR) ; Piccardi, Nathalie; (Saint
Egreve, FR) |
Correspondence
Address: |
FOLEY AND LARDNER
SUITE 500
3000 K STREET NW
WASHINGTON
DC
20007
US
|
Assignee: |
Laboratoires Expanscience
|
Family ID: |
29724931 |
Appl. No.: |
10/519096 |
Filed: |
December 27, 2004 |
PCT Filed: |
June 25, 2003 |
PCT NO: |
PCT/FR03/01956 |
Current U.S.
Class: |
514/27 ;
514/456 |
Current CPC
Class: |
A61K 8/4973 20130101;
A61K 8/9789 20170801; A61K 8/9794 20170801; A61Q 19/08 20130101;
A61K 8/602 20130101; A61K 8/02 20130101; A61K 8/9711 20170801; A61K
8/9771 20170801; A61K 8/046 20130101 |
Class at
Publication: |
514/027 ;
514/456 |
International
Class: |
A61K 031/7048; A61K
031/353 |
Foreign Application Data
Date |
Code |
Application Number |
Jun 27, 2002 |
FR |
0207995 |
Claims
1-19. (canceled)
20. A treatment method for promoting slimming, for fighting
localized excess weight, refining the silhouette, accelerating the
removal of excesses, better defining the contour of the body and/or
resculpturing the silhouette, said method comprising applying a
composition comprising one or more isoflavones in a glycone or
glycosylated form.
21. The method of claim 20, wherein the composition is a topical
composition.
22. The method of claim 20, wherein the composition is a cosmetic
composition.
23. The method of claim 20, wherein applying a composition is
directed to a skin of a patient.
24. The method of claim 20, wherein applying a composition is
implemented topically.
25. The method of claim 20, wherein the isoflavone is genistein,
daidzein, glycitein or a mixture thereof.
26. The method of claim 25, wherein the genistein is from soy.
27. The method of claim 20, further comprising applying one or two
slimming agents of lipolytic type, one or two slimming agents of
liporeducing type or a combination thereof.
28. The method of claim 27, wherein the agent of lipolytic type is
caffeine, rhodysterol, palmitoylcarnitine, alpha bioactive agent,
gamma bioactive agent, escin, ginkgo biloba or sphingosine.
29. The method of claim 27, wherein the agent of liporeducing type
is andiroba, Garcinia cambogia or rutin.
30. The method of claim 20, further comprising applying one or two
anti-filtration or venotonic agents, wherein said antifiltration or
venotonic agent is viburnum, ivy, arnica, mouseear hawkweed, wild
pansy, Fucus vesiculosus, Ruscus, Gingko biloba or escin.
31. The method of claim 20, further comprising applying an extract
of Sophora japonica flowers, an extract of Centella asiatica, soy
protein or any combination thereof.
32. A cosmetic composition, comprising one or more isoflavones in a
glycone or glycosylated form and an extract of Sophora japonica
flowers.
33. The cosmetic composition of claim 32, wherein the isoflavone is
genistein, daidzein, glycitein or a mixture thereof.
Description
[0001] Use of isoflavones for preparing topical compositions for
promoting slimming, and related cosmetic treatment method.
[0002] The present invention relates to the use of isoflavones for
the preparation of topical compositions that are useful for
promoting slimming, and to the related cosmetic treatment
method.
[0003] In the context of the present invention, slimming is
preferentially a case of fighting localized excess weight.
[0004] This localized excess weight appears in the form of fat, the
amount and distribution of which differ according to the sex. Thus,
adipose tissue represents 20 to 30% of the body weight in women and
10 to 15% in men. Subcutaneous fat is twice as thick in women as in
men. In men, fat accumulates around and above the waistline
(android distribution, metabolic risk factor) and below the
waistline, in the gluteo-femoral region in women (gynoid
distribution, not correlated with a vascular risk). One of the
characteristics of this accumulated lower body fat is that it is
difficult to mobilize. It is intended to ensure the energetic needs
of reproduction (pregnancy and, above all, breastfeeding) and thus
constitutes the largest energy reservoir in the body.
[0005] At the cellular level, adipocytes are spherical cells whose
intracellular space is occupied by a large vacuole filled with
triglycerides. The adipocytes can change rapidly in volume.
Specifically, depending on the circumstances, these cells may reach
40 .mu.m to 120 .mu.m in diameter, which corresponds to a 27-fold
increase in volume. In certain extreme cases, this increase may be
up to 40-fold. Thus, the adipocyte is the main energy factor in the
body since it is capable of rapidly storing (uptake or lipogenesis)
or, conversely, mobilizing (lipolysis) the triglycerides, which are
the main energy sources of the body.
[0006] Lipogenesis proceeds via the synthesis of triacylglycerols,
which result from the esterification of glycerol 3-phosphate with
activated fatty acids; conversely lipolysis corresponds to the
hydrolysis of the stored triacylglycerols, to glycerol and fatty
acids. Various mechanisms have been brought to light, which control
lipolysis and lipogenesis and involve, for example, receptors such
as the alpha-2 and/or beta-1 and -2 receptors, the type A1
adenosine receptors, the prostaglandin E2, Y2 of YY type and the
neuropeptide NPY receptors, but also sexual hormones.
[0007] Thus, the knowledge of the mechanisms controlling adipocyte
lipolysis and lipogenesis has been very markedly improved. However,
slimming active agents are still sought, since the known slimming
active agents are not entirely satisfactory. There is thus at the
present time a genuine demand to develop topical compositions for
efficiently promoting slimming.
[0008] Two major types of slimming active agents are known:
lipolytic agents (acting on the removal of the excess lipids) and
liporeducing agents (combating the formation of fat).
[0009] a) Lipolytic Agents
[0010] Caffeine (which is found in many plants: green tea, guarana
seeds): inhibits phosphodiesterase, thus ensuring an optimum
intracellular level of cAMP, stimulates the .beta. receptors and
inhibits the lipoprotein lipase;
[0011] rhodysterol (extract of a red alga): activates the .alpha.
receptors and promotes the penetration of caffeine;
[0012] palmitoyl-carnitine: accelerates the combustion of fatty
acids, by improving their uptake by the mitochondria;
[0013] alpha and gamma bioactive agents (derived, respectively,
from a marine bacterium and a fungus): block the .alpha.2 and NPY
receptors;
[0014] escin and ginkgo biloba: .alpha.2 blockers;
[0015] sphingosine: limits the penetration of glucose;
[0016] b) Liporeducing Agents
[0017] Andiroba (triterpenes) and Carcina cambogia: block the
conversion of the preadipocytes into adipocytes;
[0018] rutin: (extracted from Ruta graveolens): isolates glucose
and prevents it from combining with free fatty acids.
[0019] To these specific active agents may be added
anti-infiltration active agents and venotonic agents, which are
often combined with slimming active agents.
[0020] Anti-Infiltration Active Agents:
[0021] Viburnum (draining, decongesting, active caffeine effect,
free-radical scavenging, firming)
[0022] Anti-inflammatory, anti-edematous, analgesic
[0023] Arnica (anti-edematous, calmative)
[0024] Mouseear hawkweed (free-radical scavenging, accelerates
draining)
[0025] Wild pansy (important role in water balance)
[0026] Fucus vesiculosus (anti-edematous, calmative)
[0027] Venotonic Agents:
[0028] Ruscus (vitamin P action, vascular tonic)+
[0029] Ginkgo biloba (fights vascular and capillary stasis)
[0030] Escin (improvement in venous tonus, modifies the capillary
permeability)
[0031] Finally, formulations comprising these known slimming active
agents can be complemented with restructuring and smoothing active
agents that fight sagging of the skin.
[0032] It has now been found that the application of a topical
composition comprising one or more isoflavones has a slimming
action and makes it possible especially to fight localized excess
weight.
[0033] Patent application WO 01/64177 (Henkel KGAA) discloses the
use of a composition comprising a flavone, an isoflavone, or
glycosyl and optionally a substance for stimulating and/or
depolarizing the nerve fibers, for the cosmetic treatment of
cellulite or firming of the skin.
[0034] In the article Cosmetics, D. Schmid et al., SFW-Journal,
127. Jahrgang 10-200, "Genisteine, a new cosmetic ingredient
derived from soy", the anti-cellulite action of certain isoflavones
is described. However, cellulite is a condition that is quite
different from localized excess weight.
[0035] Thus, cellulite is defined as a localized metabolic disorder
of the subcutaneous tissues that causes an impairment in the shape
of the body. Conversely, excess weight is caused by hypertrophy or
hyperplasia of the adipocytes (increase in lipogenesis), or a
reduction in lipolysis. The cellulite-slimming differentiation also
appears in view of the fact that cellulite affects the dermis
(subcutaneous tissue) of women only, whereas excess weight (the
adipocytes) affects both sexes. Furthermore, cellulite appears in
women even without excess weight; it is a problem of
dermal/hypodermal architecture.
[0036] Patent application EP 829 261 relates to compositions
comprising isoflavones for their weight-reducing effect via the
degradation of fat accumulated in the fat cells. However, the
topical mode of administration is not mentioned in said patent
application.
[0037] One subject of the present invention is thus the use of
isoflavones for the preparation of topical compositions that are
useful for promoting slimming, and the related cosmetic treatment
method.
[0038] The "isoflavones" that may be used according to the present
invention may be natural substances extracted from natural
products, especially from plants such as soybean, clover, lupin,
apple seeds, etc. The topical compositions according to the present
invention quite often contain, as isoflavones, a mixture of
different isoflavones, but they may also be present in pure form in
the context of the present invention. Moreover, the aglycone forms
of the isoflavones and the glycosylated forms thereof are
distinguished. These various forms are usually found as a mixture.
They are illustrated by the following formulae.
[0039] Aglycone forms, of formula: 1
[0040] in which R'.sub.1 represents a hydrogen atom or a hydroxyl
group, R'.sub.2 represents a hydrogen atom or a methoxy group and
R'.sub.3 represents a hydroxyl group.
[0041] Advantageously, according to the present invention,
R'.sub.1, R'.sub.2 and R'.sub.3 represent:
1 R'.sub.1 R'.sub.2 R'.sub.3 Compound name H H OH daidzein OH H OH
genistein H OCH.sub.3 OH glycitein
[0042] Glycosylated forms, of formula: 2
[0043] in which R'.sub.4 represents a hydrogen atom or a hydroxyl
group, R'.sub.5 represents a hydrogen atom or a methoxy group and
R'.sub.6 represents a hydrogen atom.
[0044] Advantageously, according to the present invention,
R'.sub.4, R'.sub.5 and R'.sub.6 represent:
2 R'.sub.4 R'.sub.5 R'.sub.6 Compound name H H H daidzine OH H H
genistine H OCH.sub.3 H glycitine
[0045] The glycosylated forms of the isoflavones are the ones that
are the most abundant in nature.
[0046] The isoflavones that are preferred are the natural
isoflavones such as genistein (1), daidzein or glycitein. 3
[0047] In particular, genistein, or 4,5,7-trihydroxy-isoflavone,
which may be used according to the present invention may be a
product of plant origin and especially from soybean, with a titer
of 85% to 90% by weight of genistein, especially the product sold
by the company Buckton Scott under the name "85%-titer
genistein".
[0048] The isoflavones may be used alone or as a mixture in the
context of the present invention.
[0049] The topical application of a composition of one or more
isoflavones may prove to be particularly advantageous in the case
of pregnant women or women who have given birth within 6 months. A
subject of the present invention is thus also a cosmetic treatment
method for promoting slimming and especially for fighting localized
excess weight in pregnant women or women who have given birth
within 6 months. Specifically, one of the advantages of the
compositions that may be used in the context of the present
invention is that the presence of alcohol, which is contraindicated
for pregnant and breastfeeding women on account of its toxicity, is
not necessary. Specifically, caffeine, a very commonly used
slimming agent, requires dissolution in alcohol, which is thus
avoided in the context of the present invention.
[0050] According to the present invention, the terms "slimming" and
"fighting localized excess weight" mean an action making it
possible to avoid or at the very least reduce the formation of
subcutaneous fat as described previously. This action is especially
reflected by a reduction in unsightly excesses or reserves, by
refining the silhouette, by accelerating the removal of excesses,
and by a better definition of the contour of the body or
alternatively a resculptured silhouette.
[0051] According to the present invention, the expression "cosmetic
treatment method for fighting localized excess weight" means the
use of a cosmetic treatment that makes it possible to visibly
measure the action described above.
[0052] Thus, a topical composition comprising one or more
isoflavones used according to the invention may be applied to the
areas of skin liable to form this localized excess weight, namely
areas where these excesses have already formed or are in the
process of being formed.
[0053] By way of example, a composition containing genistein that
may be used in the context of the present invention may contain
between 0.0085% and 8.5% of genistein by weight relative to the
total weight of the composition, i.e. for a solution with an 85% to
90% by weight titer of genistein, between 0.01% and 10% by weight
of this solution relative to the total weight of the
composition.
[0054] More generally, a composition containing one or more
isoflavones that may be used in the context of the present
invention may contain between 0.01% and 10%, and preferably from
0.1% to 3%, by weight of isoflavone(s) relative to the total weight
of the composition.
[0055] The composition that allows the invention to be implemented
comprises a cosmetically acceptable support, i.e. a support that is
compatible with the skin, and may be in any galenical form normally
used for topical application, especially in the form of an aqueous,
aqueous-alcoholic or oily solution, an oil-in-water or water-in-oil
or multiple emulsion, an aqueous or oily gel, a liquid, pasty or
solid anhydrous product, a dispersion of oil in an aqueous phase
with the aid of spherules, these spherules possibly being polymer
nanoparticles such as nanospheres and nanocapsules or better still
lipid vesicles of ionic and nonionic type.
[0056] This composition may be more or less fluid and may have the
appearance of a white or colored cream, an ointment, a milk, a
lotion, a serum, a paste, a mousse or a gel.
[0057] It may optionally be applied to the skin in the form of an
aerosol. It may also be in solid form, for example in the form of a
stick.
[0058] The composition of the invention may also contain adjuvants
that are common in cosmetics, such as hydrophilic or lipophilic
gelling agents, hydrophilic or lipophilic active agents, preserving
agents, antioxidants, solvents, fragrances, chelating agents, odor
absorbers and dyestuffs. The amounts of these various adjuvants are
those conventionally used in the fields under consideration, for
example from 0.01% to 20% of the total weight of the composition.
Depending on their nature, these adjuvants may be introduced into
the fatty phase, into the aqueous phase, into lipid vesicles or
into nanoparticles.
[0059] When the composition of the invention is an emulsion, the
proportion of the fatty phase may range from 5% to 80% and
preferably from 5% to 50% by weight relative to the total weight of
the composition. The oils, emulsifiers and coemulsifiers used in
the composition in emulsion form are chosen from those
conventionally used in the field under consideration. The
emulsifier and coemulsifier are present in the composition in a
proportion ranging from 0.3% to 30% and preferably from 0.5% to 20%
by weight relative to the total weight of the composition.
[0060] As oils that may be used in the compositions for
implementing the invention, mention may be made of mineral oils,
oils of plant origin (apricot oil, sunflower oil or plum oil), oils
of animal origin, synthetic oils, silicone oils and fluoro oils
(perfluoropolyethers). Fatty alcohols (cetyl alcohol), fatty acids
and waxes (beeswax) may also be used as fatty substances.
[0061] As emulsifiers and coemulsifiers that may be used in the
invention, examples that may be mentioned include fatty acid esters
of polyethylene glycol, such as PEG-40 stearate and PEG-100
stearate, and fatty acid esters of polyols, such as glyceryl
stearate and sorbitan tristearate.
[0062] Hydrophilic gelling agents that may be mentioned in
particular include carboxyvinyl polymers (carbomer), acrylic
copolymers such as acrylate/alkylacrylate copolymers,
polyacrylamides, polysaccharides, natural gums and clays, and
lipophilic gelling agents that may be mentioned include modified
clays, for instance bentones, metal salts of fatty acids,
hydrophobic silica and polyethylenes.
[0063] The composition used according to the invention may contain
other active agents with a slimming action, for instance the
lipolytic agents and liporeducing agents as described in the
introduction.
[0064] The invention thus relates to the use of isoflavones for the
preparation of topical compositions that are useful for promoting
slimming and especially for fighting localized excess weight,
characterized in that one or more isoflavones and also one or two
slimming active agents of lipolytic type and/or one or two slimming
active agents of liporeducing type are applied, simultaneously,
separately or sequentially over time.
[0065] The slimming active agent of lipolytic type may be chosen
from: caffeine, rhodysterol, palmitoylcarnitine, alpha and gamma
bioactive agents, escin, ginkgo biloba and sphingosine. The
slimming active agent of liporeducing type may be chosen from:
andiroba, Garcinia cambogia and rutin.
[0066] One or two anti-infiltration or venotonic active agents may
also be applied simultaneously, separately or sequentially over
time in addition to the application of the composition used
according to the invention. The anti-infiltration or venotonic
active agents may be chosen from: viburnum, ivy, arnica, mouseear
hawkweed, wild pansy, Fucus vesiculosus, Ruscus, ginkgo biloba and
escin.
[0067] The composition used according to the invention may also
comprise other active agents, such as:
[0068] an extract of Sophora japonica flowers: this extract is rich
in flavanoids (free-radical-scavenging) and in rutin. This active
agent promotes the capillary circulation, facilitating and
activating the draining and anti-infiltrations of tissues;
[0069] extract of Centella asiatica: extract of Centella, a plant
originating from east Africa and from Madagascar. This active agent
contains terpenes (asiaticosides, asiatic acid and madecassic acid)
with draining, anti-infiltration and firming properties on tissues.
It is especially used in slimming products, but also in
anti-stretch mark, anti-wrinkle and siccatrizing products; 0 to 5%
extract of Centella may thus be present in a slimming
composition;
[0070] "Hydrolyzed Soy Protein": soy protein, which is an
elastoregulator. These soy peptides may be any peptide obtained by
hydrolysis of proteins extracted from soy, according to operating
conditions known to those skilled in the art, in other words any
soy protein hydrolysate. Soy peptides, which are described in
patent application WO 00/19974, are particularly suitable for
introduction into the compositions used in the context of the
present invention. This active agent allows restoration of the
mechanisms of cell renewal, activates the synthesis of the
structural components of the extracellular matrix and has a
restructuring, regenerating and firming action; 0 to 5% soy protein
may thus be present in a slimming composition;
[0071] anti-wrinkle active agents, among which mention may be made
of avocado furans, retinol and its derivatives, vitamin C or
unsaponifiable matter from soy, etc.
[0072] The combination of the two active agents: isoflavone taken
alone or as a mixture, and extract of Sophora japonica flowers, is
particularly preferred and a composition containing this
combination forms part of the invention. Such a composition may
contain from 0.01% to 20% of extract of Sophora japonica
flowers.
[0073] The examples that follow illustrate the present
invention.
EXAMPLE 1
Restructuring Gel
[0074]
3 Ingredients (INCI - EU) % w/w Aqua qsp PEG-6 3.6000 Butylene
glycol 2.7000 Dextrin 1.8600 Phenyl trimethicone 1.2000
Acrylates/C10-30 alkyl acrylate 0.6000 crosspolymer Preservative
system qsp Dimethicone/phenyl vinyl 0.3000 dimethicone crosspolymer
Fragrance qs Sophora japonica flower extract 0.01 to 20 Xanthan gum
0.1500 PPG 26-Buteth-26 0.1100 Genosten .RTM. 4000.sup.(1) 1 to 10
Hydrolyzed soy protein 0.1000 Glucose 0.0800 PEG 40 hydrogenated
castor oil 0.0700 Sorbitol 0.0400 Centella asiatica extract 0.01 to
5 Citric acid 0.0200 Enteromorpha compressa extract 0.01 to 5
Colorant qs Sodium hydroxide qsp pH = 4.5 to 6.5 qs = quantity
sufficient qsp = quantity sufficient for .sup.(1)sold by the
company Nutrinov
[0075] Isoflavone-rich soy extract obtained by physical
extraction:
[0076] 4% isoflavones including:
4 Daidzine: 0.28 g O. Malonyl daidzine: 0.93 g Genistine: 0.28 g O.
Malonyl genistine: 2.50 g Genistein: 0.02 g Daidzein: 0 g
EXAMPLE 2
Restucturing Gel
[0077]
5 Ingredients (INCI - EU) %w/w Aqua qsp PEG-6 3.6000 Butylene
glycol 2.7000 Dextrin 1.8600 Phenyl trimethicone 1.2000
Acrylates/C10-30 alkyl acrylate 0.6000 crosspolymer Preservative
system qsp Dimethicone/phenyl vinyl 0.3000 dimethicone crosspolymer
Fragrance qs Sophora japonica flower extract 0.01 to 20 Xanthan gum
0.1500 PPG 26-Buteth-26 0.1100 4,5,7-trihydroxyisoflavone 0.01 to
10 Hydrolyzed soy protein 0.1000 Glucose 0.0800 PEG 40 hydrogenated
castor oil 0.0700 Sorbitol 0.0400 Centella asiatica extract 0.01 to
5 Citric acid 0.0200 Enteromorpha compressa extract 0.01 to 5
Colorant qs Sodium hydroxide qsp pH = 4.5 to 6.5 qs = quantity
sufficient qsp = quantity sufficient for
EXAMPLE 3
Oil-in-Water Cream
[0078]
6 Ingredients (INCI - EU) % w/w Aqua qsp Squalane 5.00 Petrolatum
5.00 Glycerin 5.00 Isodecyl neopentanoate 5.00 Pentaerythrityl 5.00
tetraethylhexanoate Cyclomethicone 4.00 Cetearyl alcohol 3.00
Myristyl myristate 2.00 Laureth-23 2.00 Silica 2.00 Heptadecadienyl
furan 0.1 to 10 Beeswax 1.00 Sclerotium gum 1.00 PEG-6 1.00
Polyacrylamide 0.80 Glyceryl stearate 0.70 Dimethiconol 0.70
Cetearyl glucoside 0.60 C13-14 isoparaffin 0.40 Citric acid 0.14
Laureth-7 0.10 Quimdis mixture.sup.(2) 0.01 to 10 Caffeine 0.1 to
10 Enteromorpha compressa extract 0.01 to 5 Garcinia cambogia
extract 0.01 to 10 Ginkgo biloba extract 0.01 to 10 Sophora
japonica flower extract 0.01 to 20 Hydrolyzed soy protein 0.01 to
10 Preservative system qs Fragrance qs qs = quantity sufficient qsp
= quantity sufficient for .sup.(2)sold by the company Quimdis
[0079] Mixture of isoflavones between 7 and 17%
[0080] 4 to 8% daidzein glycosides
[0081] 2 to 5% glycitine glycosides
[0082] 1 to 4% genistein glycosides
EXAMPLE 4
Oil-in-Water Cream
[0083]
7 Ingredients (INCI - EU) % w/w Aqua qsp Squalane 5.00 Petrolatum
5.00 Glycerin 5.00 Isodecyl neopentanoate 5.00 Pentaerythrityl 5.00
tetraethylhexanoate Cyclomethicone 4.00 Cetearyl alcohol 3.00
Myristyl myristate 2.00 Laureth-23 2.00 Silica 2.00 Heptadecadienyl
furan 0.1 to 10 Beeswax 1.00 Sclerotium gum 1.00 PEG-6 1.00
Polyacrylamide 0.80 Glyceryl stearate 0.70 Dimethiconol 0.70
Cetearyl glucoside 0.60 C13-14 isoparaffin 0.40 Citric acid 0.14
Laureth-7 0.10 4,5,7-Trihydroxyisoflavone 0.01 to 10 Caffeine 0.1
to 10 Enteromorpha compressa extract 0.01 to 5 Garcinia cambogia
extract 0.01 to 10 Ginkgo biloba extract 0.01 to 10 Sophora
japonica flower extract 0.01 to 20 Hydrolyzed soy protein 0.01 to
10 Preservative system qs Fragrance qs qs = quantity sufficient qsp
= quantity sufficient for
EXAMPLE 5
Water-in-Oil Cream
[0084]
8 Ingredients (INCI - EU) % w/w Aqua qsp Hydrogenated polyisobutene
7.00 Isocetyl stearate 7.00 Cyclomethicone 4.80 Glycerin 4.00
Mineral oil 3.00 Zinc oxide 3.00 Butylene glycol 2.00 Isononyl
isononanoate 2.00 Beeswax 2.00 Cetyl dimethicone copolyol 1.70
Polyglyceryl-4 isostearate 1.65 Hexyl laurate 1.65 Disodium
tartrate 1.60 Sodium chloride 1.00 PEG-6 1.00
4,5,7-Trihydroxyisoflavone 0.01 to 10 Retinyl palmitate 0.01 to 10
Enteromorpha compressa extract 0.01 to 5 Sophora japonica flower
extract 0.01 to 20 Centella asiatica extract 0.01 to 5 Hydrolyzed
soy protein 0.01 to 10 Preservative system qs Fragrance qs qs =
quantity sufficient qsp = quantity sufficient for
EXAMPLE 6
Lipstick
[0085]
9 Ingredients (INCI - EU) % w/w Castor oil qsp Oleyl alcohol 20.00
Hydrogenated palm kernel oil 17.00 Candelilla wax 11.00
Polyglyceryl-3 beeswax 10.00 Mineral oil 9.57 Heptadecadienyl furan
0.1 to 1 4,5,7-Trihydroxyisoflavone 0.01 to 1.10 quaternium-18
hectorite Titanium dioxide 1.00 Tocopheryl acetate 0.50 Propylene
carbonate 0.33 Fragrance qs Retinol 0.01 Enteromorpha compressa
extract 0.01 to 5 Sophora japonica flower extract 0.01 to 20
Centella asiatica extract 0.01 to 5 Hydrolyzed soy protein 0.01 to
10 qs = quantity sufficient qsp = quantity sufficient for
EXAMPLE 7
Cream Gel
[0086]
10 Ingredients (INCI - EU) % w/w Aqua qsp Cyclomethicone 5.40 Octyl
palmitate 5.00 Hydrogenated cocoglycerides 3.00 Arachidyl behenyl
alcohol 2.55 Propylene glycol 2.50 Isodecyl neopentanoate 2.00
Glyceryl stearate 1.70 Cetyl alcohol 1.30 Stearic acid 1.00 PEG-6
1.00 Beeswax 0.40 C13-14 isoparaffin 0.40 Butylene glycol 0.16
Glycerin 0.16 Cetearyl alcohol 0.10 Cetyl palmitate 0.10
Cocoglycerides 0.10 Laureth-7 0.10 Novasoy mixture.sup.(3) 0.01 to
10 Enteromorpha compressa extract 0.01 to 5 Sophora japonica flower
extract 0.01 to 20 Centella asiatica extract 0.01 to 5 Hydrolyzed
soy protein 0.01 to 10 Preservative system qs Fragrance qs qs =
quantity sufficient qsp = quantity sufficient for .sup.(3)sold by
the company ADM
[0087] Mixture of isoflavones at 30% minimum
[0088] Genistein/diadzine/glycitine ratio: 1.3/1.0/0.3
[0089] Dosage example:
11 genistein: 20.80% glycitine: 3.80% daidzein: 12.00%
EXAMPLE 8
Cream Gel
[0090]
12 Ingredients (INCI - EU) % w/w Aqua qsp Cyclomethicone 5.40 Octyl
palmitate 5.00 Hydrogenated cocoglycerides 3.00 Arachidyl behenyl
alcohol 2.55 Propylene glycol 2.50 Isodecyl neopentanoate 2.00
Glyceryl stearate 1.70 Cetyl alcohol 1.30 Stearic acid 1.00 PEG-6
1.00 Beeswax 0.40 C13-14 isoparaffin 0.40 Butylene glycol 0.16
Glycerin 0.16 Cetearyl alcohol 0.10 Cetyl palmitate 0.10
Cocoglycerides 0.10 Laureth-7 0.10 4,5,7-Trihydroxyisoflavone 0.01
to 10 Enteromorpha compressa extract 0.01 to 5 Sophora japonica
flower extract 0.01 to 20 Centella asiatica extract 0.01 to 5
Hydrolyzed soy protein 0.01 to 10 Preservative system qs Fragrance
qs qs = quantity sufficient qsp = quantity sufficient for
EXAMPLE 9
Spray
[0091]
13 Ingredients (INCI - EU) % w/w Aqua qsp Glycerin 4.00
Montmorillonite 3.00 PEG 3.00 Glycine 0.30 Citric acid 0.09
4,5,7-Trihydroxyisoflavone 0.01 to 10 Enteromorpha compressa
extract 0.01 to 5 Sophora japonica flower extract 0.01 to 20
Centella asiatica extract 0.01 to 5 Hydrolyzed soy protein 0.01 to
10 Preservative system qs Fragrance qs qs = quantity sufficient qsp
= quantity sufficient for
EXAMPLE 10
Summary of the Test of Use of the Restructuring Gel According to
Example 1
[0092] It was sought in this test to assess the efficacy and
acceptability of the restructuring gel according to example 1,
after repeated applications, twice a day over a period of 8 weeks,
under the normal conditions of use, by a group of 92 to 100
consumers who had given birth within 3 months and/or whose body
skin (midriff and thighs) had excess fat.
[0093] Panelists
[0094] The analysis of the results related to a panel of 92 (T 2
months) to 100 (T 1 month) consumers, the physical characteristics
of which are given below.
[0095] Panel at T 1 Month (100 Consumers)
14 Panel at T 1 month (100 consumers) "Sensitive" Age Nature of the
body skin skin 19 to 49 years old dry: 44% 35% (average: 30 years
normal: 36% old) dry-normal combination: 20%
[0096] It should be noted that 48 panelists had just been through
their first pregnancy, 44 had had previous pregnancies numbering 2
(23), 3 (20) and 4 (1).
[0097] Panel at T 2 Months (92 Consumers)
15 "Sensitive" Age Nature of the body skin skin 19 to 49 years old
dry: 45% 37% (average: 30 years old) normal: 33.7% dry-normal
combination: 20%
[0098] It should be noted that 48 panelists had just been through
their first pregnancy, and that 40 had had previous pregnancies
numbering 2 (21) or 3 (19).
[0099] Protocol
[0100] The restructuring gel studied was applied twice a day on
average (morning and evening), for 1 to 2 months, to the body
(thighs, hips, midriff and buttocks in particular), by the
consumers, at home, under the normal conditions of use, instead of
the product they generally used.
[0101] The questionnaires, adapted to the nature of the product,
were filled in at the end of the test (T1 and T2 months) and then
mailed in, and especially included the questions listed below
relating to the action of fighting excess weight.
[0102] The restructuring gel according to example 1, applied for 2
months by the 92 to 100 women described above was found
particularly favorable, since 87% of the panelists judged it as
overall "pleasant" to "very pleasant" and 67% judged it as overall
"good" to "very good". The performance characteristics below were
demonstrated.
16 Effects at T 1 month Effects at T 2 months (100 consumers) (92
consumers) Peformance Expressed as % of the panel Reduced unsightly
76 86 excesses Reduced unsightly 70 80 reserves Refined silhouette
75 87 "Accelerates" the 74 86 removal of excesses Models the body
70 90 Body contours better 77 68 defined The silhouette is 60 --
resculptured
* * * * *